Jalra is a diabetes medicine that is used together with diet and exercise to control the blood glucose (sugar) in adults with type 2 diabetes. It is used alone when metformin (another diabetes medicine) is not suitable, or together with other diabetes medicines, including insulin, when these medicines do not provide adequate control of the blood glucose. Jalra contains the active substance vildagliptin.
Therapeutic Indication
### Therapeutic indication Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: - as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
Therapeutic Area (MeSH)
ATC Code
A10BH02
ATC Item
vildagliptin
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| vildagliptin | N/A | 维格列汀 |
EMA Name
Jalra
Medicine Name
Jalra
Aliases
N/ANo risk management plan link.
